Paper Details

  1. Home
  2. Paper Details

A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine.

Author: BancroftW, BinnL N, CohenD, GreenM S, HokeC, LermanY, RobinG, SjogrenM, SleponR, ZurS

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

A new inactivated hepatitis A vaccine showed high immunogenicity and no significant side effects.
Paper Details　
Original Abstract of the Article :
Purified, formaldehyde-inactivated and alum-adjuvanted hepatitis A virus (HAV) vaccines have recently become available for clinical trials. The vaccine is administered intramuscularly in a schedule of 0, 1, and 6 months. The aim of the study was to evaluate the reactogenicity and immunogenicity of a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8034508

データ提供：米国国立医学図書館（NLM）

Inactivated Hepatitis A Vaccine: A Safe Oasis in the Desert of Viral Infections

This research delves into the realm of [vaccine development], focusing on the safety and efficacy of an [inactivated hepatitis A vaccine]. The study, involving [volunteers], evaluated the [reactogenicity] and [immunogenicity] of this new vaccine. The authors discovered that the [inactivated hepatitis A vaccine] elicited a robust [immune response] with minimal [side effects]. This finding suggests that the vaccine could be a valuable tool in preventing [hepatitis A], offering a safe and effective way to protect individuals from this potentially serious viral infection.

A Safe Haven in the Desert: The Promise of Inactivated Hepatitis A Vaccine

This research provides compelling evidence for the safety and efficacy of [inactivated hepatitis A vaccine], offering a promising avenue for protecting individuals from this potentially debilitating viral infection. The study's findings encourage wider adoption of this vaccine, ensuring greater protection for vulnerable populations and contributing to the control of [hepatitis A] globally.

Navigating the Sands of Viral Infections: Prevention as the Best Medicine

This research underscores the importance of [vaccination] in protecting individuals from preventable viral infections. The study's findings serve as a reminder that vaccines are a powerful tool in preventing [hepatitis A] and other infectious diseases. By embracing vaccination, we can effectively navigate the deserts of viral infections, ensuring a healthier and safer future for all.

Dr. Camel's Conclusion

Just as a camel relies on its internal reserves to survive the harsh desert, we can rely on vaccines to build our immune defenses against infectious diseases. This study, like a wellspring in the arid landscape, reveals the promise of inactivated hepatitis A vaccine, offering a safe and effective way to protect ourselves from this potentially debilitating viral infection. By embracing vaccination, we can navigate the desert of viral infections with greater confidence and resilience, ensuring a healthier and more secure future for ourselves and our communities.

Date :
  1. Date Completed 1994-08-12
  2. Date Revised 2006-11-15
Further Info :

Pubmed ID

8034508

DOI: Digital Object Identifier

8034508

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.